Cardionerds: A Cardiology Podcast

CardioNerds Critical Care Cardiology Council members Dr. Gurleen Kaur and Dr. Katie Vanchiere meet with Dr. Yash Patel, Dr. Akanksha, and Dr. Mohammed El Nayir from Trinity Health Ann Arbor. They discuss a case of pulmonary air embolism, RV failure, and cardiac arrest secondary to an ocular venous air embolism. Expert insights provided by Dr. Tanmay Swadia. Audio editing by CardioNerds Academy intern, Grace Qiu. A 36-year-old man with a history of multiple ocular surgeries, including a complex retinal detachment repair, suffered a post-vitrectomy collapse at home. He was found hypoxic, tachycardic, and hypotensive, later diagnosed with a pulmonary embolism from ocular venous air embolism leading to severe right heart failure. Despite a mild embolic burden, the cardiovascular response was profound, requiring advanced hemodynamic support, including an Impella RP device (Abiomed, Inc.). Multidisciplinary management, including fluid optimization, vasopressors and mechanical support to facilitate recovery. This case underscores the need for early recognition and individualized intervention in cases of ocular venous air embolism. “To study the phenomena of disease without books is to sail an uncharted sea, while to study books without patients is not to go to sea at all.” – Sir William Osler. CardioNerds thank the patients and their loved ones whose stories teach us the Art of Medicine and support our Mission to Democratize Cardiovascular Medicine. Enjoy this Circulation 2022 Paths to Discovery article to learn about the CardioNerds story, mission, and values. US Cardiology Review is now the official journal of CardioNerds! Submit your manuscript here. CardioNerds Case Reports PageCardioNerds Episode PageCardioNerds AcademyCardionerds Healy Honor Roll CardioNerds Journal ClubSubscribe to The Heartbeat Newsletter!Check out CardioNerds SWAG!Become a CardioNerds Patron! Pearls- Clear Vision, Clouded Heart: Ocular Venous Air Embolism with Pulmonary Air Embolism, RV Failure, and Cardiac Arrest Hypoxia, hypotension and tachycardia in a patient following ocular instrumentation are classic findings suggestive of pulmonary embolism from possible air embolism. The diagnosis of RV failure is based on clinical presentation, echocardiographic findings (such as McConnell’s sign), and invasive hemodynamic assessment via right heart catheterization. Mechanical circulatory support can be considered as a temporary measure for patients with refractory RV failure. Central Figure: Approach to Pulmonary Embolism with Acute RV Failure Notes – Clear Vision, Clouded Heart: Ocular Venous Air Embolism with Pulmonary Air Embolism, RV Failure, and Cardiac Arrest 1. What is an Ocular Venous Air Embolism (VAE), and how can it be managed in critically ill patients? An Ocular Venous Air Embolism is defined as the entry of air into the systemic venous circulation through the ocular venous circulation, often during vitrectomy procedures. Early diagnosis is key to preventing cardiovascular collapse in cases of Ocular Venous Air Embolism (VAE).  The goal is to stop further air entry. This can be done by covering the surgical site with saline-soaked dressings and checking for air entry points. Adjusting the operating table can help, especially with a reverse Trendelenburg position for lower-body procedures. The moment VAE is suspected, discontinue nitrous oxide and switch to 100% oxygen. This helps with oxygenation, speeds up nitrogen elimination, and shrinks air bubbles. Hyperbaric Oxygen Therapy can reduce bubble size and improve oxygenation, especially in cases of cerebral air embolism, when administered within 6 hours of the incident. Though delayed hyperbaric oxygen therapy can still offer benefits, the evidence is mixed. VAE increases right heart strain, so inotropic agents like dobutamine can help boost cardiac output, while norepinephrine supports ventricular function and systemic vascular resistance, but this may also worsen pulmonary resistance.  Aspiration of air via multi-orifice or Swan-Ganz catheters has limited success, with success rates ranging from 6% to 16%. In contrast, the Bunegin-Albin catheter has shown more promise, with a 30-60% success rate. Catheterization for acute VAE-induced hemodynamic compromise is controversial, and there’s insufficient evidence to support its widespread emergency use. 2. What are the key hemodynamic parameters used to assess RV function? On echocardiogram, there are a number of parameters that can assess RV function:  Tricuspid Annular Plane Systolic Excursion (TAPSE): Measures the lateral tricuspid annulus’ movement during systole. A TAPSE value below 1.6 cm is associated with poor prognosis. RV Outflow Tract (RVOT) Acceleration Time: Measured via pulsed wave Doppler, an acceleration time of <100 ms is abnormal, with values ≤60 ms indicating a worse prognosis. Global RV Longitudinal Strain: Assessed via speckle tracking, with a strain value of −20% being highly predictive of RV dysfunction (normal values typically range -24.5 to -28.5%). Tricuspid Regurgitation (TR) Jet Velocity: Helps estimate pulmonary systolic pressure and provides prognostic information. Inferior Vena Cava (IVC) Collapsibility: Useful in estimating right atrial pressure and guiding volume resuscitation, though it lacks prognostic significance. The RV:LV diameter ratio offers prognostic value, with a ratio greater than 0.9  linked to worse outcomes. Invasive Hemodynamic Monitoring (Right heart catheterization, PA Catheter) The Pulmonary Artery Pulsatility Index (PAPI) is an invasive hemodynamic parameter used to assess right ventricular (RV) function, particularly in cases of RV failure and cardiogenic shock. PAPi is the pulmonary arterial pulse pressure divided by the RA pressure. A PAPi of <0.9 is a poor indicator, especially in the acute myocardial infarction population. 3. What are the core principles in managing a patient with RV failure?  The management to optimize RV function is centered around optimizing preload, afterload, and contractility. Optimizing preload – Optimizing preload is one of the most important aspects in the management of acute decompensated RV failure. The majority of us are taught that the RV is “preload dependent” and patients should be fluid resuscitated. However, many patients are actually volume overloaded and may benefit from diuresis. Overall, this is a patient-to-patient decision, depending on the clinical picture, to optimize preload; though the use of pulmonary artery (PA) catheters in this setting is not well supported. Reducing afterload – Avoid intubation if clinically feasible, as they may increase PVR; however, if essential, ideally, oxygen saturation (SaO₂) should be maintained above 92%, and ventilator settings should be adjusted to optimize lung volume and maintain a normal pH and PCO₂. Nitric oxide has also been beneficial in improving oxygenation and reducing PVR with its vasodilatory effects. Support cardiac output May support with the use of inotropes as well as mechanical circulatory support. Pressors: The ideal vasopressor increases systemic arterial pressure and RV contractility without raising pulmonary vascular resistance. Norepinephrine: Primarily an α1 agonist, it improves systemic blood pressure with some β1 stimulation. It has shown benefits in maintaining RV-PA coupling. Dobutamine: A β1 agonist that improves myocardial contractility and RV-PA coupling, though it can cause vasodilation at higher doses. In general, dobutamine is considered the best for acute RVF with PH, unless hypotension is a significant concern, in which case norepinephrine might be preferred. Milrinone is another option. MCS: short-term MCS should be considered in patients with cardiogenic shock as a bridge to recovery, a bridge to decision, or a bridge to bridge whilst the underlying causes for cardiogenic shock are addressed further described below Options include: Venous-arterial extracorporeal membranous oxygenation (V-A ECMO) RA to PA extracorporeal pump. (surgical RVAD) Flow device with an intake in the RA and an output in the PA. (Impella RP, Protek Duo) 4. When should we consider mechanical circulatory support for right ventricular (RV) failure? Short-term MCS should be considered in patients with cardiogenic shock as a bridge to recovery, a bridge to decision, or a bridge to bridge whilst the underlying causes for cardiogenic shock are addressed. Clinical parameters that suggest acute MCS use include signs of relative hypoperfusion plus hemodynamic features suggestive of RV failure, which were present in our patient. A specific additional consideration relates to where acute left-sided MCS reveals acute RV failure. Discerning whether this is intrinsic RV failure or due to persistently elevated RV afterload from inadequate LV support is also essential, as it will define management.  The goal of percutaneous mechanical support is to bypass the right ventricle and improve hemodynamics, while allowing time for optimization of the patient and recovery of the RV.  References Arrigo, Mattia, et al. “Diagnosis and Treatment of Right Ventricular Failure Secondary to Acutely Increased Right Ventricular Afterload (Acute Cor Pulmonale). A Clinical Consensus Statement of the Association for Acute CardioVascular Care (ACVC) of the ESC.” European Heart Journal. Acute Cardiovascular Care, vol. 13, no. 3, 22 Dec. 2023, pp. 304–312, https://doi.org/10.1093/ehjacc/zuad157. Accessed 17 May 2024. Chen, Guohai, et al. “INCIDENCE of ENDOPHTHALMITIS after VITRECTOMY: A Systematic Review and Meta-Analysis.” Retina (Philadelphia, Pa.), vol. 39, no. 5, May 2019, pp. 844–852, pubmed.ncbi.nlm.nih.gov/29370034/, https://doi.org/10.1097/IAE.0000000000002055. Fakkert, Raoul A, et al. “Early Hyperbaric Oxygen Therapy Is Associated with Favorable Outcome in Patients with Iatrogenic Cerebral Arterial Gas Embolism: Systematic Review and Individual Patient Data Meta-Analysis of Observational Studies.” Critical Care, vol. 27, no. 1, 12 July 2023, https://doi.org/10.1186/s13054-023-04563-x. Accessed 7 June 2024. Flaxel, Christina J., et al. “Idiopathic Epiretinal Membrane and Vitreomacular Traction Preferred Practice Pattern®.” Ophthalmology, vol. 127, no. 2, Feb. 2020, pp. P145–P183, https://doi.org/10.1016/j.ophtha.2019.09.022. Accessed 16 July 2020. Frémont, Benoît, et al. “Prognostic Value of Echocardiographic Right/Left Ventricular End-Diastolic Diameter Ratio in Patients with Acute Pulmonary Embolism.” Chest, vol. 133, no. 2, Feb. 2008, pp. 358–362, https://doi.org/10.1378/chest.07-1231. Huang, Ryan S, et al. “Pars Plana Vitrectomy with Silicone Oil or Gas Tamponade for Uncomplicated Retinal Detachment: A Systematic Review and Meta-Analysis.” American Journal of Ophthalmology, vol. 266, Oct. 2024, pp. 144–155, pubmed.ncbi.nlm.nih.gov/38815844/, https://doi.org/10.1016/j.ajo.2024.05.008. Kanwar, Manreet K, et al. “Epidemiology and Management of Right Ventricular-Predominant Heart Failure and Shock in the Cardiac Intensive Care Unit.” European Heart Journal. Acute Cardiovascular Care, vol. 11, no. 7, 29 June 2022, pp. 584–594, https://doi.org/10.1093/ehjacc/zuac063. Accessed 5 Mar. 2023. Lahm, Tim, et al. “Medical and Surgical Treatment of Acute Right Ventricular Failure.” Journal of the American College of Cardiology, vol. 56, no. 18, Oct. 2010, pp. 1435–1446, www.onlinejacc.org/content/56/18/1435, https://doi.org/10.1016/j.jacc.2010.05.046. Accessed 30 Nov. 2019. Mirski, Marek A., et al. “Diagnosis and Treatment of Vascular Air Embolism.” Anesthesiology, vol. 106, no. 1, 1 Jan. 2007, pp. 164–177, pubs.asahq.org/anesthesiology/article/106/1/164/8884/Diagnosis-and-Treatment-of-Vascular-Air-Embolism, https://doi.org/10.1097/00000542-200701000-00026. Accessed 13 Apr. 2021. Moon, Young Eun. “Venous Air Embolism during Vitrectomy: A Rare but Potentially Fatal Complication.” Korean Journal of Anesthesiology, vol. 67, no. 5, 1 Jan. 2014, pp. 297–297, pmc.ncbi.nlm.nih.gov/articles/PMC4252339/, https://doi.org/10.4097/kjae.2014.67.5.297. Accessed 10 Mar. 2025. “Right Ventricular Failure.” Escardio.org, 2016, www.escardio.org/Journals/E-Journal-of-Cardiology-Practice/Volume-14/Right-ventricular-failure. Stickel, Simone, et al. “The Practical Management of Fluid Retention in Adults with Right Heart Failure due to Pulmonary Arterial Hypertension.” European Heart Journal Supplements, vol. 21, 1 Dec. 2019, pp. 46–53, academic.oup.com/eurheartjsupp/article/21/Supplement_K/K46/5678698, https://doi.org/10.1093/eurheartj/suz207. Ventetuolo, Corey E., and James R. Klinger. “Management of Acute Right Ventricular Failure in the Intensive Care Unit.” Annals of the American Thoracic Society, vol. 11, no. 5, 1 June 2014, pp. 811–822, www.ncbi.nlm.nih.gov/pmc/articles/PMC4225807/#:~:text=Abstract, https://doi.org/10.1513/AnnalsATS.201312-446FR. Accessed 10 Aug. 2020. What Is Vitrectomy. “What Is Vitrectomy?” American Academy of Ophthalmology, 15 May 2019, www.aao.org/eye-health/treatments/what-is-vitrectomy. Zhao, Steven, and Oren Friedman. “Management of Right Ventricular Failure in Pulmonary Embolism.” Critical Care Clinics, vol. 36, no. 3, July 2020, pp. 505–515, https://doi.org/10.1016/j.ccc.2020.02.006. Accessed 29 Nov. 2020. 239. CCC: Approach to RV Predominant Cardiogenic Shock with Dr. Ryan Tedford

In this engaging discussion, Dr. Allison Tsao, an interventional cardiologist, shares insights on cutting-edge techniques in congenital heart disease care. Dr. Jill Steiner emphasizes the importance of palliative care, focusing on the emotional well-being of patients. Dr. Katherine Salciccioli explores the intersection of ACHD and cardio-obstetrics, discussing the complexities of pregnancy for patients with congenital heart issues. Together, they tackle the emotional landscape of care, the significance of building trust, and the essential role of compassion in patient-provider relationships.

In this discussion, Dr. Namrita Ashokprabhu, a clinical research coordinator at the Women's Heart Center, Dr. Mehmet Yildiz, a second-year cardiology fellow, and Dr. Yulith Roca Alvarez, a physician starting her cardiology fellowship, dive into the complexities of MINOCA. They explore the critical role of cardiac MRI in diagnosing coronary vasospasm and myocarditis. The team emphasizes the importance of tailored treatments like calcium channel blockers and the challenges of invasive testing methods to manage this intricate cardiovascular condition.

Join Spencer Weintraub, Chief Resident of Internal Medicine, Michael Albosta, a third-year resident, and Zahid Ahmad, an Associate Professor specializing in lipid disorders, as they unravel a compelling case of hypertriglyceridemia. They discuss its link to acute pancreatitis in a woman with a complex medical history, emphasizing diagnosis challenges and management strategies. The conversation dives into lifestyle changes, innovative therapies, and the critical role of nutrition in controlling triglyceride levels, offering valuable insights for preventing cardiovascular complications.

Dr. Sri Mandava, a cardiology fellow at Mount Sinai Medical Center, and Dr. Pranav Venkataraman, an attending physician, delve into a gripping case involving cardiac sarcoidosis presenting as a STEMI in a 57-year-old man. They discuss the challenges of diagnosing unusual STEMI without typical coronary artery disease, emphasizing the role of advanced imaging techniques. The complexities of managing cardiac sarcoidosis and the importance of interdisciplinary collaboration to prevent sudden cardiac events are also highlighted, showcasing critical decision-making in cardiology.

Dr. Daniel Judge, a leading expert in cardiovascular genetics at the Medical University of South Carolina, shares his insights on transthyretin amyloid cardiomyopathy (ATTR-CM). The discussion highlights the importance of recognizing subtle symptoms like ventricular hypertrophy and carpal tunnel syndrome. Dr. Judge also dives into innovative treatments, including gene-silencing technologies and antibody-based therapies, emphasizing the rapid advancements in this field. His passion for early diagnosis and improving patient outcomes shines throughout the conversation.

Dr. Jeff Healey, a pioneer in ventricular arrhythmias research, and Dr. Roderick Tung, an expert in arrhythmia management, delve into the VANISH2 trial's crucial findings. They discuss the effectiveness of catheter ablation versus antiarrhythmic drugs for patients with ischemic cardiomyopathy. The conversation highlights the trial's impact on treatment choices and patient outcomes, emphasizing the importance of tailored interventions. Additionally, they explore the complexities of managing non-ischemic cardiomyopathy and address safety considerations in arrhythmia therapies.

Nikita Mishra and Rohan Ganti are first-year cardiology fellows at Rutgers-Robert Wood Johnson, while Sabahat Bokhari is a recognized professor and center director. They delve into a puzzling case of a 61-year-old man experiencing refractory ventricular tachycardia, requiring extensive defibrillation efforts. The discussion covers diagnostic strategies for hypertrophic cardiomyopathy, the complexities of medication management, and the critical role of advanced imaging. They also highlight tools to enhance clinician support and the importance of multidisciplinary collaboration in patient care.

Dr. Prashanthan Sanders, a leader in atrial fibrillation prevention, and Dr. Mehak Dhande, an electrophysiologist focusing on lifestyle changes, discuss the groundbreaking ARREST-AF trial. They reveal how an intensive risk factor management program significantly improved outcomes for atrial fibrillation patients. Topics include successful lifestyle modifications like weight loss and better management of health conditions, along with strategies to enhance patient education and access to care. Their insights emphasize the need for tailored approaches in cardiovascular health.

Milton Packer, a pioneer in heart failure research with over 500 publications, joins the discussion on the groundbreaking SUMMIT trial. The trial investigated tirzepatide's impact on obese heart failure patients, revealing reduced risks of cardiovascular death and enhanced quality of life. The conversation covers key insights from recent trials, the effectiveness of managing heart failure alongside obesity, and the collaboration between academia and industry in medical research. Packer sheds light on the trial's strengths, limitations, and the need for further exploration in weight management.